Description
Cardiogen (Ala-Glu-Asp-Arg) is a synthetic tetrapeptide of the Khavinson bioregulator class with tissue-specific action on the cardiovascular system. The substance was developed at the St. Petersburg Institute of Bioregulation and Gerontology for investigating age-related cardiac gene expression changes.
Per study reports Cardiogen activates the Khavinson class’s epigenetic pathway: short peptides bind to DNA regulator regions and modulate gene activity in cardiac muscle tissue. Preclinical studies describe effects on protein synthesis in cardiomyocytes and normalization of age-related cardiac markers.
Russian research literature documents data accumulated over years on Cardiogen from animal studies and limited human studies. International replication from Western European or US laboratories remains very limited - the data is primarily centered on the Khavinson institute.
Typical application is in 10-20 day courses two to three times per year. Subcutaneous or intramuscular injection.
You can order Cardiogen as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Cardiogen is classified as very mild in the available literature and is among the most well tolerated compounds of the Khavinson class. In the available preclinical and limited human research, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous or intramuscular use is the most common observation. The tetrapeptide itself is considered low-reactivity.
- Very thin human data: the data base is primarily centered on the Khavinson institute and consists of small, predominantly Russian-language studies. International peer-reviewed replication is largely absent, and robust long-term data on the cardiovascular safety profile do not exist.
- Course-based pattern: the use described in the literature occurs in short 10-20 day courses. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation - Cells 2022, Khavinson et al: review of bioregulator effects on cardiovascular cell senescence and inflammaging.
- Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation in aging - Advances in Gerontology 2015, Khavinson et al: mechanism paper on peptidergic regulation of aging endothelial cells.
- Studies of the Effects of Vilon and Epithalon on Gene Expression in Mouse Heart using DNA-Microarray Technology - Bulletin of Experimental Biology and Medicine 2002, Anisimov et al: DNA microarray study of cardiac gene expression under Khavinson peptides.
- Peptide bioregulation of aging: results and prospects - Biogerontology 2010, Anisimov and Khavinson: aging mechanism review of the bioregulator class.
